Ophthalmic Therapeutic Innovation
Ophthalmic Therapeutic Innovation
  • Home
  • About OTI
    • Mission
    • Vision
    • History
    • Contact Us
  • Pipelines & Partners
  • Breakthrough Discovery
  • Glaucoma
  • Team
  • Publications
  • News
  • More
    • Home
    • About OTI
      • Mission
      • Vision
      • History
      • Contact Us
    • Pipelines & Partners
    • Breakthrough Discovery
    • Glaucoma
    • Team
    • Publications
    • News
  • Home
  • About OTI
    • Mission
    • Vision
    • History
    • Contact Us
  • Pipelines & Partners
  • Breakthrough Discovery
  • Glaucoma
  • Team
  • Publications
  • News

Redefine Glaucoma Patient Care by IOP Normalization & Tissue Rejuvenation

Redefine Glaucoma Patient Care by IOP Normalization & Tissue RejuvenationRedefine Glaucoma Patient Care by IOP Normalization & Tissue RejuvenationRedefine Glaucoma Patient Care by IOP Normalization & Tissue Rejuvenation

OTI-2024, first in class and best in class adenosine drug, a new MMP agent removes the rate-limiting root causes of glaucoma

Redefine Glaucoma Patient Care by IOP Normalization & Tissue Rejuvenation

Redefine Glaucoma Patient Care by IOP Normalization & Tissue RejuvenationRedefine Glaucoma Patient Care by IOP Normalization & Tissue RejuvenationRedefine Glaucoma Patient Care by IOP Normalization & Tissue Rejuvenation

OTI-2024, first in class and best in class adenosine drug, a new MMP agent removes the rate-limiting root causes of glaucoma

Copyright © OTI 2025 -  All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept